MedElevator Войти в исследования
← Поиск публикаций

DOI 10.17235/reed.2025.11653/2025

Медицинская библиотека · Revista espanola de enfermedades digestivas · 2025

Biosimilar switching in IBD: safety, efficacy, and immunogenicity in 10,812 patients - A systematic review and meta-analysis.

Zheng Dian-Yu, Zhou Li-Ying, Huang Yu-Hong, Jiang Min, Dai Cong

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Biosimilars of infliximab and adalimumab are increasingly adopted in inflammatory bowel disease (IBD) to reduce healthcare costs, but concerns persist regarding their long-term efficacy, immunogenicity, and safety post-switch. This meta-analysis synthesizes contemporary evidence on outcomes after transitioning from originators to biosimilars.

METHODS

We systematically searched PubMed, Embase, MEDLINE, and conference abstracts (inception-June 2025) to identify randomized controlled trials (RCTs) and observational studies comparing biosimilars (CT-P13, SB2, SB5, etc.) with originators in IBD. Primary outcomes included clinical remission, discontinuation rate, adverse events (AEs), C-reactive protein (CRP), and fecal calprotectin (FCAL), and anti-drug antibody (ADA) incidence. Risk of bias was assessed using Cochrane and Newcastle-Ottawa tools. Pooled odds ratios (ORs) and event rates were calculated using random-effects models.

RESULTS

Among 37 studies (36 observational, 1 RCTs) encompassing 10812 IBD patients, biosimilars demonstrated comparable clinical remission rates pre- and post-switch in Crohn's disease (CD) (OR = 0.87, 95% CI: 0.74-0.96) and ulcerative colitis (UC) (OR = 1.25, 95% CI: 0.83-1.90). Biomarkers (CRP, fecal calprotectin) remained stable post-transition. Pooled discontinuation rates were 13% (range: 2-36%) after switching. Safety profiles were similar between biosimilars and originators, ADA incidence (OR = 0.96, 95% CI: 0.46-2.02) showed no significant differences. Heterogeneity stemmed from differences in follow-up duration, disease subtype (CD vs. UC), and variable outcome definitions.

CONCLUSION

Biosimilars maintain comparable efficacy, safety, and immunogenicity to originators in IBD, supporting their use in single or multiple switching scenarios. Standardized reporting of mucosal healing, drug monitoring, and economic metrics is critical to optimize biosimilar adoption in real-world practice.

Для цитирования: Zheng Dian-Yu, Zhou Li-Ying, Huang Yu-Hong, Jiang Min, Dai Cong. Biosimilar switching in IBD: safety, efficacy, and immunogenicity in 10,812 patients - A systematic review and meta-analysis.. Revista espanola de enfermedades digestivas. 2025. DOI: 10.17235/reed.2025.11653/2025.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.